Silicone Oil Microdroplets and Protein Aggregates in Repackaged Bevacizumab and Ranibizumab: Effects of Long-term Storage and Product Mishandling
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
PURPOSE: To quantify levels of subvisible particles and protein aggregates in repackaged bevacizumab obtained from compounding pharmacies, as well as in samples of bevacizumab and ranibizumab tested in controlled laboratory experiments. METHODS: Repackaged bevacizumab was purchased from four external compounding pharmacies. For controlled laboratory studies, bevacizumab and placebo were drawn into plastic syringes and incubated at -20°C, 4°C, and room temperature (with and without exposure to light) for 12 weeks. In addition, mechanical shock occurring during shipping was mimicked with syringes containing bevacizumab. Particle counts and size distributions were quantified by particle characterization technology. Levels of monomer and soluble aggregates of bevacizumab were determined with size-exclusion high-performance liquid chromatography (SE-HPLC). RESULTS: Repackaged bevacizumab from the compounding pharmacies had a wide range of particle counts (89,006 ± 56,406 to 602,062 ± 18,349/mL). Bevacizumab sampled directly from the original glass vial had particle counts of 63,839 ± 349/mL. There was up to a 10% monomer loss in the repackaged bevacizumab. Laboratory samples of repackaged bevacizumab and placebo had initial particle counts, respectively, of 283,675 ± 60,494/mL and 492,314 ± 389,361/mL. Freeze-thawing of both bevacizumab and placebo samples led to >1.2 million particles/mL. In all repackaged samples, most of the particles were due to silicone oil. SE-HPLC showed no significant differences for repackaged samples incubated in the laboratory under various conditions, compared with bevacizumab directly from vial. However, repeated freeze-thawing caused a more than 10% monomer loss. CONCLUSIONS: Bevacizumab repackaged in plastic syringes could contain protein aggregates and is contaminated by silicone oil microdroplets. Freeze-thawing or other mishandling can further increase levels of particle contaminants.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Exposure to light has been shown to increase particulate count by 2.5 times [58].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Protein aggregates can form under a variety of circumstances prior to intravitreal injection of the drug and they can be further induced by SO release from syringes [57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Various factors can contribute to SO release from the inner cylinder wall, protein denaturing, or both [55, 57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Freeze-thawing that may occur during shipping has been demonstrated to significantly increase SO microdroplet release in bevacizumab solution, along with increased protein particle levels [58].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Many processes involved in the shipping, handling and storage of anti-VEGF medications and syringes can contribute to SO release and protein aggregation [55, 57–59].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [58]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RICH, R. M., ROSENFELD, P. J., PULIAFITO, C. A., DUBOVY, S. R., DAVIS, J. L., FLYNN, H. W., GONZALEZ, S., FEUER, W. J., LIN, R. C., LALWANI, G. A., et al. (2006) · Retina · doi:10.1097/01.iae.0000225766.75009.3a · Cited by 484
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
Silicone Oil- and Agitation-Induced Aggregation of a Monoclonal Antibody in Aqueous Solution
Thirumangalathu, R., Krishnan, S., Ricci, M. S., Brems, D. N., Randolph, T. W., & Carpenter, J. F. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21719 · Cited by 294
Self-citationSustained elevation of intraocular pressure after intravitreal injections of anti-VEGF agents
Good, T. J., Kimura, A. E., Mandava, N., & Kahook, M. Y. (2011) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.180729 · Cited by 245
Self-citationSilicone oil induced glaucoma: A review
Ichhpujani, P., Jindal, A., & Jay Katz, L. (2009) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-009-1155-x · Cited by 204
Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions
Ludwig, D. B., Carpenter, J. F., Hamel, J., & Randolph, T. W. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21982 · Cited by 137
Self-citationHIGH-MOLECULAR-WEIGHT AGGREGATES IN REPACKAGED BEVACIZUMAB
Kahook, M. Y., Liu, L., Ruzycki, P. A., Mandava, N., Carpenter, J. F., Petrash, J. M., & Ammar, D. A. (2010) · Retina · doi:10.1097/iae.0b013e3181d50cea · Cited by 130
Self-citationPersisent ocular hypertension following intravitreal ranibizumab
Bakri, S. J., McCannel, C. A., Edwards, A. O., & Moshfeghi, D. M. (2008) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0819-2 · Cited by 129
Sustained Elevation in Intraocular Pressure Associated With Intravitreal Bevacizumab Injections
Kahook, M. Y., KIMURA, A. E., Wong, L. J., Ammar, D. A., Maycotte, M. A., & Mandava, N. (2009) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20090430-12 · Cited by 127
Self-citationSubramanian, M. L., Abedi, G., Ness, S. D., Ahmed, E., Fenberg, M. J., Daly, M. K., Houranieh, A. M., & Feinberg, E. B. (2010) · Eye · doi:10.1038/eye.2010.147 · Cited by 105
Research works printed but not linked: 2
- [15]15. Sharma DK Oma P, Krishnan S. Silicone microdroplets in protein formulations detection and enumeration. Pharm Technol 2009;33: 74-79.
- [18]18. Crampton S, Ricci M. Development and Application of a Fourier Transform Infrared (FTIR) Spectroscopy Method to Quantify Silicone Oil Extracted from Syringes. AAPS National BioTechnology. Conference. San Francisco: The American Association of Pharmaceutical Scientists; 2010.
Cited by
Items 101–200 of 206
Pruimboom‐Brees, I., Gupta, S., Chemuturi, N. V., Booler, H. S., Nimz, E. L., Ramos, M. F., Caruso, A., Maass, K. F., Bantseev, V., Huang, Q., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13480 · Cited by 14
Ricci, F., Calabrese, A., Felici, C. D., Missiroli, F., Pileri, M., & Regine, F. (2016) · Digital Journal of Ophthalmology · doi:10.5693/djo.01.2016.03.001 · Cited by 14
Cappelletto, E., Kwok, S. C., Sorret, L. L., Fuentes, N., Medina, A. M., Burleigh, S., Fast, J. L., Mackenzie, I. S., Millqvist‐Fureby, A., Paulsson, M., et al. (2024) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2024.05.027 · Cited by 13
“39,92,94 Although silicone oil at the levels present in these devices is unlikely to introduce toxicological and immunological risks, 95 the complexity of DP delivery devices requires clear instructions for pharmacists to prepare, for the nurses to administer, and for the patients to monitor.”
Effect of silicone oil on the structure, stability, and aggregation of a therapeutic antibody
Upadhyay, V., Panja, S., Krishnamachari, Y., Mittal, S. N., Xi, H., Xu, W., Song, J., Hu, G., Su, Y., & Mallela, K. M. G. (2025) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2025.103848 · Cited by 13
Wang, T., Joshi, S. B., Kumru, O. S., Telikepalli, S. N., Middaugh, C. R., & Volkin, D. B. (2013) · Springer eBooks · doi:10.1007/978-1-4614-4316-2_9 · Cited by 15
Nanji, K., Sarohia, G. S., Kennedy, K., Ceyhan, T., McKechnie, T., Phillips, M., Devji, T., Thabane, L., Kaiser, P. K., Sarraf, D., et al. (2021) · Ophthalmology · doi:10.1016/j.ophtha.2021.11.024 · Cited by 14
Effect of Processing Parameters on the Physical Stability of Silicone Coatings
Dixit, N., Maloney, K. M., & Kalonia, D. S. (2012) · AAPS PharmSciTech · doi:10.1208/s12249-012-9843-y · Cited by 12
“The physical leaching of silicone oil can occur because of the mechanical shock encountered by a lubricated device during different processes such as product filling, shipping, or freeze–thaw (4,13).”
BackgroundCallanan, D., Khurana, R. N., Maturi, R. K., Patel, S. S., Wykoff, C. C., Eichenbaum, D. A., Khanani, A. M., Hassan, T., Badger, H., Mehta, S., et al. (2023) · Clinical ophthalmology · doi:10.2147/opth.s405994 · Cited by 13
Kim, N. A., Noh, G. Y., Hada, S., Na, K. J., Yoon, H.-J., Park, K.-W., Park, Y.-M., & Jeong, S. H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.06.176 · Cited by 11
Ichiyama, Y., Sawada, T., Kakinoki, M., Sawada, O., Nakashima, T., Saishin, Y., Kawamura, H., & Ohji, M. (2014) · Ophthalmic Research · doi:10.1159/000365253 · Cited by 11
Sisk, R. A., Rusia, D., Zamora, B. G., Kuley, A., & Toussaint, B. W. (2018) · Retina · doi:10.1097/iae.0000000000002314 · Cited by 10
Sarao, V., Veritti, D., Bonini, F., Martin, A. A., & Lanzetta, P. (2025) · Eye · doi:10.1038/s41433-025-03765-7 · Cited by 10
Off-label use of plastic syringes with silicone oil for intravenous infusion bags of antibodies
Kim, N. A., Hada, S., Kim, D. J., Choi, D. H., & Jeong, S. H. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.07.001 · Cited by 10
Nisha, P., Srushti, P., Bhavarth, D., Kaif, M., & Parikh, P. K. (2023) · Current Pharmaceutical Analysis · doi:10.2174/0115734129270020231102081109 · Cited by 9
Mansoori, T., Agraharam, S. G., Manwani, S., & Balakrishna, N. (2021) · Journal of Current Ophthalmology · doi:10.4103/joco.joco_5_20 · Cited by 9
García, S. B., Garrell-Salat, X., Trejo-Velasco, F., Aragón-Roca, D., Zapata, M. Á., & García‐Arumí, J. (2022) · BMC Ophthalmology · doi:10.1186/s12886-022-02536-2 · Cited by 9
“For this reason, it has been hypothesized that direct obstruction of the trabecular meshwork due to the presence of high molecular weight proteins and the passage of these silicone bubbles into the anterior chamber could be a cause of increased intraocular pressure [9, 13].”
BackgroundRuane, S., Li, Z., Hollowell, P., Hughes, A. V., Warwicker, J., Webster, J. R. P., van der Walle, C. F., Kalonia, C. K., & Lu, J. R. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c00864 · Cited by 9
Aflibercept clearance through the drainage system in a rat model
Keshet, Y., Gal‐Or, O., Schaap‐Fogler, M., Mimouni, K., Ishai, M. B., Weinberger, D., & Dotan, A. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00322-8 · Cited by 9
Parakh, S., Bhatt, V., Das, S. M., Lakhlan, P., Luthra, G., & Luthra, S. (2024) · Cureus · doi:10.7759/cureus.75937 · Cited by 10
“In addition, delivery-related factors such as syringe agitation, silicone oil-induced protein aggregates in the syringe, freeze-thawing processes, as well as shipping and handling procedures may all lead to inflammation [11,14,15].”
Huet, F., Miller, J. M., Miller, P. E., Hayden, C. M., Glick, J. J., Bentley, A., Benedetto, C. D., McPherson, L. E., & Turner, O. C. (2020) · Toxicologic Pathology · doi:10.1177/0192623320966543 · Cited by 8
“These structures had thicker walls and, as in the 14-week study, appeared identical to those described as silicone oil droplets in humans dosed with a variety of biologics in a clinical setting.(4,5,7,13,14) The affected animals in the historical studies also exhibited no appreciable impact on vision associated with t…”
BackgroundKim, N. A., Yu, H. W., Noh, G. Y., Park, S.-K., Kang, W., & Jeong, S. H. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.07.012 · Cited by 8
Bagheri, S., Ntentakis, D. P., Emfietzoglou, M., Ashourizadeh, H., Grinspan, N., Ploumi, I., Armstrong, G. W., & Miller, J. B. (2025) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000580 · Cited by 7
Schargus, M., Kopp, K. T., Helbig, C., Фрингс, А., & Winter, G. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.9.21 · Cited by 7
Moll, F., Bechtold-Peters, K., & Frieß, W. (2023) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2023.07.015 · Cited by 6
Üçgül, A. Y., Aktaş, Z., Özgür, A., Çubuk, M. Ö., Hasanreisoğlu, M., Özdek, Ş., & Gürelik, G. (2020) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001600 · Cited by 6
Sanabria, M. R., Alonso‐Tarancón, A. M., Monar, P. S. C., Ibañez, P., de Arriba, S. G., Alvarez, N., González, J. A. P., Coco, R. M., & Fernández, I. (2021) · Acta Ophthalmologica · doi:10.1111/aos.14743 · Cited by 6
Keane, P. A., Tufail, A., & Patel, P. J. (2011) · Journal of Ophthalmology · doi:10.1155/2011/752543 · Cited by 7
“Other studies have demonstrated the presence of particulate contaminates—with the risk of inflammatory reaction— following the preparation of bevacizumab for intraocular use [14, 65]; such findings emphasize the need for implementation of stringent protocols when preparing these drugs.”
Barbosa, B. R. D., Barbosa, S. F., Tavares, G. D., Bou‐Chacra, N. A., & Pinto, T. D. J. A. (2014) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502011000100006 · Cited by 6
“…observed significant differences on the amount of bevacizumab between syringes resulting from fractioning, with an increase of up to 10 times in particulate material when compared to the original ampoule, and with contamination of silicone oil microparticles (Kahook et al., 2010; Liu et al., 2011).”
BackgroundStorey, P. P., Ho, V. Y., Yeh, S., Reddy, S., Fang-Yen, N. H., Pequignot, E. C., Leiby, B. E., Fineman, M. S., Garg, S. J., Hubbard, G. B., et al. (2015) · Retina · doi:10.1097/iae.0000000000000620 · Cited by 6
“One eye with preexisting glaucoma only had one follow-up visit after developing sustained OHT.”
BackgroundInfluentialUchino, T., Miyazaki, Y., Ohkawa, T., Yamazaki, T., Yanagihara, Y., Yoshimori, T., Komatsu, M., Suzuki, H., & Kagawa, Y. (2015) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c15-00242 · Cited by 6
Characterization of Polymeric Syringes Used for Intravitreal Injection
Peláez, S. S., Mahler, H., Koulov, A. V., Joerg, S., Matter, A., Vogt, M., Chalus, P., Zäh, M., Sediq, A. S., Jere, D., et al. (2020) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.06.003 · Cited by 6
Tawfik, G. M., Shahein, E. A., Dabour, S. A., Hassanein, D. H., & Elshewy, A. M. (2022) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2022-001173 · Cited by 5
“Failed initial plus regression in the IVB group in our study may be explained by deterioration of the intrinsic properties of the molecule or the potency of the drug as a result of the repackaging into plastic syringes 36 or duration of the storage.”
Kaiser, P. K., Yun, J., Kim, S., Kim, J., & Park, S. J. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-022-00645-1 · Cited by 5
“Previous research showed that bevacizumab and ranibizumab withdrawn into plastic syringes were contaminated with SO microdroplets [24, 25].”
BackgroundMethodRahhal, F. M., Hu, A. Y. H., Humayun, M. S., George, M. S., Javid, C. G., Brown, J., Pitcher, J. D., Dagnon, T., & Kissner, J. (2024) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20240924-01 · Cited by 5
Bae, S. S., Koenigstein, D., Weaver, T., Merkur, A. B., Albiani, D. A., Pakzad-Vaezi, K. L., & Kirker, A. W. (2021) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2021.06.025 · Cited by 5
Fujiwara, S., Ueda, T., Ishii, N., Abe, Y., Hayashihara, K., Takeda, K., Kurinomaru, T., Fukuhara, A., Uchiyama, S., & Carpenter, J. F. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2021.09.003 · Cited by 5
Self-citationHada, S., Na, K. J., Jeong, J., Choi, D. H., Kim, N. A., & Jeong, S. H. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123439 · Cited by 5
Assessment of bevacizumab quality and stability in repackaged syringes for clinical use
Santoveña-Estévez, A., Sánchez-Negrín, E., Gutiérrez, F., Nazco, J., & Fariña, J. B. (2016) · European Journal of Hospital Pharmacy · doi:10.1136/ejhpharm-2015-000853 · Cited by 5
Touma-Falci, L., Neto, C. A. M., Taleb, A. C., Prieto, M. B., Packer, T., Oliveira, J. C. B., Birck, M. G., Julian, G. S., & Forestiero, F. (2021) · BMC Ophthalmology · doi:10.1186/s12886-021-02181-1 · Cited by 5
“Worth noting that previous studies showed that the process of vial sharing and repacking doses in syringes, its transportation and storage, are related to lowering the quality of the product, which increases the odds of side effects [21, 22].”
Agra, L. L. D. M., da Cruz, N. F. S., Linkuvienė, V., Carpenter, J. F., Farah, M. E., Melo, G. B., & Maia, M. (2022) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.2021-0320 · Cited by 5
“…and the fact that it is considered safe for use in the eyes, many patients with SO droplets in the vitreous have persistent complaints of floaters, which may necessitate surgical intervention in extreme cases, as well as long-term elevation of intraocular pressure and severe uveitis (9,10) .”
Self-citationHada, S., Ji, S., Lee, Y. N., Kim, K. H., Maharjan, R., Kim, N. A., Rantanen, J., & Jeong, S. H. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123091 · Cited by 5
Peterson, J. S., Rockwell, K. A., Scott, I. U., Ip, M. S., VanVeldhuisen, P., Blodi, B. A., & for the SCORE2 Investigator Group (2018) · Retina · doi:10.1097/iae.0000000000002212 · Cited by 5
Sterile Intraocular Inflammation After Intravitreal Injection—Diagnosis and Management
Greenberg, J. P., Peiris, T. J., & Lieberman, R. M. (2019) · Advances in Ophthalmology and Optometry · doi:10.1016/j.yaoo.2019.04.010 · Cited by 4
Eknure, C., Joshi, V. M., & Bachhav, Y. G. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-025-03315-0 · Cited by 4
“The result is a diminished therapeutic potency and a higher risk of adverse immune responses [56, 57].”
Tsui, J., Lau, I. H. W., Li, S. L., Chan, N. C. Y., & Young, A. L. (2021) · Hong Kong Journal of Ophthalmology · doi:10.12809/hkjo-v25n1-290 · Cited by 4
Taschauer, A., Sedivy, A., Egger, D., Angermann, R., Sami, H., Wunder, C., & Waldstein, S. M. (2024) · Eye · doi:10.1038/s41433-024-03511-5 · Cited by 5
Gil‐Martínez, M., Rodríguez‐Cid, M. J., Fenández-Rodríguez, M. I., Blanco-Teijero, M. J., Abraldes, M. J., Bandín‐Vilar, E., Zarra‐Ferro, I., González‐Barcia, M., Gómez‐Ulla, F., & Fernández‐Ferreiro, A. (2020) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2020.01.019 · Cited by 4
Fang, W., Liu, J.-W., Gao, H., Qian, Y.-C., Gao, J., & Wang, H. (2021) · Pharmaceutical Research · doi:10.1007/s11095-021-03073-1 · Cited by 4
Çevik, S. G., Cevik, M. T., & Perente, I. (2020) · Beyoglu Eye Journal · doi:10.14744/bej.2020.46855 · Cited by 4
“Additionally, protein aggregates and silicone oil microdroplets can accumulate in the bevacizumab syringes, and this accumulation can occlude the trabecular meshwork, leading to a rise in the intraocular pressure (29).”
BackgroundLow-Volume Aseptic Filling Using a Linear Peristaltic Pump
Dreckmann, T., Ludwig, I.-S., Luemkemann, J., & Huwyler, J. (2020) · PDA Journal of Pharmaceutical Science and Technology · doi:10.5731/pdajpst.2020.011858 · Cited by 4
Meduri, E., Gillmann, K., & Mansouri, K. (2021) · Journal of Glaucoma · doi:10.1097/ijg.0000000000001879 · Cited by 4
Guo, S., Li, M., Jia, Z., Xu, D., Yu, C., Mei, Y., Zhao, Y., Duan, X., Guo, X., He, P., et al. (2025) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2025.125500 · Cited by 3
Lischke, R., Rauchegger, T., Haas, G., Koubek, M., Nowosielski, Y., & Rehák, M. (2025) · International Journal of Ophthalmology · doi:10.18240/ijo.2026.01.23 · Cited by 3
“Factors such as temperature fluctuations, light exposure, and syringe agitation during shipping and preparation can increase SO release and protein aggregation [6] .”
Desideri, L. F., Fukuhara, P. S., Wintergerst, M. W. M., Meyer, C. H., Emerson, G. G., Anguita, R., & Melo, G. B. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.02.005 · Cited by 3
Quality of bevacizumab (Avastin®) repacked in single-use glass vials for intravitreal administration
Sugimoto, M. A., de Toledo, V. D. P. C. P., Cunha, M. R. R., Carregal, V. M., Jorge, R., Leão, P., Fialho, S. L., & Silva‐Cunha, A. (2017) · Arquivos Brasileiros de Oftalmologia · doi:10.5935/0004-2749.20170026 · Cited by 3
“Although the stability of bevacizumab in plastic syringes has been previously studied, no information about its repackaging into glass containers is available((15-20)).”
BackgroundMethodInfluentialFranzese, C. J., Takeuchi, K., Carabello, H., Thomas, C., Nakamura, K., Kalbermatten, A., Bajars, E., & Coyne, M. (2021) · PDA Journal of Pharmaceutical Science and Technology · doi:10.5731/pdajpst.2019.010835 · Cited by 3
Ophthalmic Product Development for Biologics
Sharma, G., Zhou, C., Wadhwa, S., Parenky, A. C., Graham, K. S., Bhalla, A. S., Liu, D., Chen, H. H., & Shameem, M. (2021) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-76367-1_17 · Cited by 3
Silicone Oil in Biopharmaceutical Containers: Applications and Recent Concerns
Dixit, N., & Kalonia, D. S. (2014) · Wiley eBooks · doi:10.1002/9781118938478.ch25 · Cited by 4
Subcutaneous suspensions of therapeutic proteins formulated as protein-coated microcrystals
Berkenhoff, K. (2013) · Elektronische Hochschulschriften der LMU München (Ludwig-Maximilians-Universität München) · doi:10.5282/edoc.15710 · Cited by 3
Rouic, J. F. L., Breger, D., Peronnet, P., Hermouet-Leclair, E., Alphandari, A., Pousset-Decré, C., Badat, I., & Becquet, F. (2016) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2016.01.007 · Cited by 2
Consenso sobre preparaciones de medicamentos intraoculares
Garay‐Aramburu, G., Herreros, J. M. A., Izquierdo, M. N., Peiró, J. F. M., Cruchaga, E. V., del Valle, F. G., & Fernández‐Vigo, J. I. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2024.11.010 · Cited by 2
Anti-VEGF Agents Clearance Through the Aqueous Outflow Pathway in a Rat Model
Ben-Arzi, A., Spector, I., Keshet, Y., Gal‐Or, O., Bahar, I., & Dotan, A. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.6.1 · Cited by 2
“14,15 20 Previous studies by our group on the same rodent model of brown Norway rat eyes showed the presence of anti-VEGF agents in the aqueous outflow pathway after a single intravitreal injection.”
Salcedo-Villanueva, G., García-Sánchez, G., Palacio-Pastrana, C., Gascón-Guzmán, G., Moreno-Andrade, A., Olvera‐Montaño, O., & Muñoz‐Villegas, P. (2025) · International Journal of Retina and Vitreous · doi:10.1186/s40942-025-00719-9 · Cited by 2
Cohen, R., Kerman, T., & Trivizki, O. (2025) · Reports — Medical Cases Images and Videos · doi:10.3390/reports8040249 · Cited by 2
“Delivery-related triggers arise from the injection system and handling and include excipient sensitivity, silicone oil microdroplets from syringes, protein aggregates generated by agitation or freeze–thaw, and occasional preparation contamination [25,28–30].”
Rahmani, K., Rajeswaren, V., Im, J., Hodges, B., & Yoganathan, P. (2026) · Retina · doi:10.1097/iae.0000000000004829 · Cited by 2
“In Liu et al. ’ s study, syringes tossed vigorously to mimic transport-Fig induced mechanical stress contained over a million particles per mL, far exceeding the particle count of undisturbed syringes.”
InfluentialKıvrak, U., Arsan, A. K., Akçay, G., Bulut, M. N., Kanar, H. S., Hacısalihoğlu, A., & Şimşek, Ş. (2024) · International Ophthalmology · doi:10.1007/s10792-024-03134-5 · Cited by 3
“In addition, freeze-thawing during shipping significantly increases silicon release [33].”
[Translated article] Consensus on intraocular drug preparations
Garay‐Aramburu, G., Herreros, J. M. A., Izquierdo, M. N., Peiró, J. F. M., Cruchaga, E. V., del Valle, F. G., & Fernández‐Vigo, J. I. (2025) · Farmacia Hospitalaria · doi:10.1016/j.farma.2025.03.004 · Cited by 3
Degrazio, D. (2015) · PDA Journal of Pharmaceutical Science and Technology · doi:10.5731/pdajpst.2015.01032 · Cited by 2
“The rate of adsorption is dependent upon the amount of surface area with which a protein has to adsorb (55).”
BackgroundInfluentialMaterial and process compatibility testing
Meyer, B. K. (2012) · Elsevier eBooks · doi:10.1533/9781908818102.67 · Cited by 2
The Anti-VEGF Epidemic: What are the Implications for Glaucoma Services?
Clement, C. I., & Skalicky, S. E. (2012) · JOURNAL OF CURRENT GLAUCOMA PRACTICE · doi:10.5005/jp-journals-10008-1106 · Cited by 2
Whither (or Wither) Adherence to Retina Trial Protocols in Clinical Practice?
Moshfeghi, D. M. (2017) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20170829-02 · Cited by 2
Валерьевич, Б. Е. (2021) · Ophthalmology Reports · doi:10.17816/ov59959 · Cited by 2
Khalil, H. E.-D. M. A., Gouda, A., & Allah, I. A. (2022) · Egyptian Journal of Medical Research · doi:10.21608/ejmr.2022.255022 · Cited by 2
Investigation of Factors Affecting Protein-Silicone Oil Interactions
Dixit, N. (2013) · OpenCommons - UConn (University of Connecticut) · Cited by 4
Raming, K., Saltenberger, I., Meinke, J., Risseeuw, S., Mercieca, K., Herrmann, P., Chang, P., Ach, T., van Leeuwen, R., Norel, J. O., et al. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.11.25 · Cited by 1
“21,22 Second, direct inflammatory processes in the trabecular meshwork cells have been described.”
Short-Term Changes in Intraocular Pressure Following Intravitreal Injection of Pegcetacoplan
Momenaei, B., Wakabayashi, T., Adams, O. E., Wang, K. Y., Regillo, C. D., Spirn, M. J., Ho, A. C., Hsu, J., Kaiser, R. S., Yonekawa, Y., et al. (2025) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264251390791 · Cited by 1
Systemic and ocular complications related to intravitreal administration of anti-VEGF agents
Köksaldı, S., Kayabaşı, M., Kartı, Ö., & Saatçi, A. O. (2026) · Medical Hypothesis Discovery & Innovation in Ophthalmology · doi:10.51329/mehdiophthal1539 · Cited by 1
Nonis, L., Alkhatib, Y., Sivakumar, B., Paulsson, M., Hartl, J., Kwok, S. C., & Sorret, L. L. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03452-0 · Cited by 1
Silicone oil in protein drug products and its implications for formulation stability
Tripathi, D. K., Lucas, A., Upadhyay, V., Fukuhara, P. S., Bespalova, A., Callegari, C., Ling, J., Melo, G. B., Su, Y., & Mallela, K. M. G. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115926 · Cited by 1
Comparison of Age-Related Macular Degeneration Treatment Trials: What did we Learn?
Csaky, K. G. (2012) · Retina · doi:10.1097/iae.0b013e3182493c05 · Cited by 1
Chan, T.-Y., & Cheng, C. (2014) · Taiwan Journal of Ophthalmology · doi:10.1016/j.tjo.2013.11.002 · Cited by 1
Intravitreal Silicone Oil Droplets after Multiple Avastin Injections
Kinker, B. (2017) · JOJ Ophthalmology · doi:10.19080/jojo.2017.02.555588 · Cited by 1
“[6] found that freeze-thawed samples of injectable Bevacizumab, along with samples that were mechanically disturbed (via dropping of package), led to large increases in intravitreal silicone oil findings.”
BackgroundGil‐Martínez, M., Rodríguez‐Cid, M. J., Fenández-Rodríguez, M. I., Blanco-Teijero, M. J., Abraldes, M. J., Bandín‐Vilar, E., Zarra‐Ferro, I., González‐Barcia, M., Gómez‐Ulla, F., & Fernández‐Ferreiro, A. (2020) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2020.01.008 · Cited by 1
Silikonöltröpfchen im Glaskörper nach intravitrealer Injektion
Bisorca‐Gassendorf, L., Januschowski, K., Guerra, N. P., Szurman, P., & Rickmann, A. (2021) · Der Ophthalmologe · doi:10.1007/s00347-021-01358-9 · Cited by 1
Pharmakologische Basis der Anti-VEGF Therapie
Schmetterer, L. F., & Garhöfer, G. (2012) · Spektrum der Augenheilkunde · doi:10.1007/s00717-012-0110-0
“Weiters kann es zu Proteinaggregaten kommen, welche wie oben erwähnt, wiederum aufgrund ihrer Größe zu einen Abflussbehinderung im Trabekelmaschenwerk führen könnten und als Konsequenz zu einer Steigerung des Intraokulardrucks [13, 14].”
BackgroundInfluentialFormulation Strategies for Recombinant Protein and Related Biotech Drugs
Winter, G., & Myschik, J. (2012) · Pharmaceutical biotechnology · doi:10.1002/9783527632909.ch10 · Cited by 1
Identification of Anomalous Features of Intravitreal Injections Using Micro-Computed Tomography
Smith, C. A., Newson, T., Hutnik, C. M. L., & Hill, K. A. (2012) · Current Eye Research · doi:10.3109/02713683.2012.744059
Frommknecht, T. (2011) · KU ScholarWorks (The University of Kansas)
Gonzalez, S., & Rosenfeld, P. J. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2012.10.008
- Self-citation
PLGA Depots for Controlled Release of Bevacizumab.
Chang, R. S. (2016) · Deep Blue (University of Michigan) · Cited by 1
Long – Term Intraocular Pressure Changes after Intravitreal Injections
Grava, S., & Laganovska, G. (2017) · Acta Chirurgica Latviensis · doi:10.1515/chilat-2017-0017
“Several mechanisms have been suggested, including trabecular damage caused by repeated intraocular pressure elevations following each injection, a direct toxic effect of the medication on trabeculum, trabeculitis caused by compounds injected, disrupted drainage of the aqueous humor by proteins of silicone particles, w…”
BackgroundAn outbreak of endophthalmitis following Intravitreal Injection of Bevacizumab in a referral center
Bukhatwa, S. A., Eldressi, S., Metmoah, E.-S., & Bukhatwa, S. (2021) · Egyptian Journal of Ophthalmology · doi:10.21608/ejomos.2021.60878.1012
Release of Silicone Oil Droplets from Off-label Syringes Used for Intravitreal Injection
Song, Y.-Y., Lee, J. H., Lee, M. W., Lee, Y. H., & Baek, S. K. (2021) · Journal of Retina · doi:10.21561/jor.2021.6.2.75
“유리체내 주사 후에 입자 오염(particle contamination)이 생 기는 문제점은 주로 bevacizumab과 관련되어 나타난다[27-29].”
Waly, M. I. (2022) · Research Square · doi:10.21203/rs.3.rs-2202271/v1
Immunological and Inflammatory Side Effects of Treatments for Age-Related Macular Degeneration
Chiang, T.-K., Kurup, S. K., & Hariprasad, S. M. (2023) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20230724-01
Andreeva, Y. S., Алхарки, Л., & Budzinskaya, M. V. (2024) · Ophthalmology Reports · doi:10.17816/ov626103
Inyecciones intravítreas, degeneración macular asociada a la edad e hipertensión ocular
Sánchez‐Monroy, J., & Rufas, I. M. (2022) · Oftalmología clínica y experimental. · doi:10.70313/2718.7446.v15.n04.186
Ambakisye, J., Mndeme, F. G., & Makupa, W. (2025) · medRxiv · doi:10.1101/2025.03.21.25324412
“…plastic syringes contained protein aggregates and silicone oil microdroplets, which could potentially block aqueous outflow or induce inflammatory trabeculitis(18).may also result from VEGF inhibition in the trabecular meshwork, reducing aqueous outflow facility, as proposed by Fujimoto et al(19).”
Ambakisye, J., Mndeme, F. G., & Makupa, W. U. (2025) · Qeios · doi:10.32388/4qe6ub
Metadata
- Authors
- Liu, L., Ammar, D. A., Ross, L. A., Mandava, N., Kahook, M. Y., & Carpenter, J. F.
- Affiliations
- University of Colorado Denver (US)
- University of Colorado Anschutz (US)
- From the Department of Pharmaceutical Sciences, Center for Pharmaceutical Biotechnology and
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2011-02-22
- Volume
- 52
- Issue
- 2
- Pages
- 1023
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- PMC
- PMC3053093
- OpenAlex
- W2031531075
- Cited by
- 199
- References
- 21
- Citations by year
- 2026: 4 · 2025: 15 · 2024: 8 · 2023: 14 · 2022: 10 · 2021: 25 · 2020: 16 · 2019: 7 · 2018: 8 · 2017: 16 · 2016: 10 · 2015: 10 · 2014: 15 · 2013: 14 · 2012: 19
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Imaging and Bioengineering (R01EB006006)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein purification and stability
- Physical Sciences › Chemistry › Analytical Chemistry › Analytical Methods in Pharmaceuticals
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- bevacizumab, ranibizumab, compounding pharmacies, protein aggregates, subvisible particles, freeze-thaw cycles, drug storage conditions, plastic syringes
- MeSH terms
- Bevacizumab, Ranibizumab, Antibodies, Monoclonal, Drug Compounding, Drug Packaging, Drug Stability, Drug Storage, Particle Size, Silicone Oils, Angiogenesis Inhibitors, Particulate Matter, Protein Multimerization, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.